Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Antigenics Raising $31.6M Via Stock Sale To Single Investor

Sep. 22, 2003

By Aaron Lorenzo and Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Tercica, Armed With Genentech Technology, Seeks $86.25M IPO

Sep. 15, 2003

By Brady Huggett

View All Articles by Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...